Theriva Biologics, Inc. Share Price

Equities

TOVX

US87164U4094

Biotechnology & Medical Research

Market Closed - Nyse 01:30:00 18/06/2024 am IST 5-day change 1st Jan Change
0.2475 USD -3.70% Intraday chart for Theriva Biologics, Inc. -4.07% -42.46%
Sales 2024 * - Sales 2025 * - Capitalization 44.4L 37Cr
Net income 2024 * -2.8Cr -233.88Cr Net income 2025 * -3.4Cr -284Cr EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-0.32 x
P/E ratio 2025 *
-0.34 x
Employees 22
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.16%
More Fundamentals * Assessed data
Dynamic Chart
Theriva Biologics Gets Fast Track Designation for Pancreatic Cancer Treatment MT
Theriva Biologics, Inc Announces U.S. Food and Drug Administration Granted Fast Track Designation CI
Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma CI
Transcript : Theriva Biologics, Inc., 2023 Earnings Call, Mar 25, 2024
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Tech in Focus on -2- DJ
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma CI
Transcript : Theriva Biologics, Inc., Q3 2023 Earnings Call, Nov 13, 2023
Theriva Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Theriva?? Biologics and Sant Joan de Deu-Bar Barcelona Children's Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer CI
Transcript : Theriva Biologics, Inc. - Special Call
Theriva? Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023 CI
Theriva Biologics, Inc. Announces Presentation at Esmo Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating Vcn-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck CI
More news
1 day-3.70%
1 week-4.07%
Current month-1.04%
1 month-33.23%
3 months-45.00%
6 months-58.07%
Current year-42.46%
More quotes
1 week
0.23
Extreme 0.23
0.26
1 month
0.23
Extreme 0.23
0.43
Current year
0.23
Extreme 0.23
0.68
1 year
0.20
Extreme 0.1972
1.20
3 years
0.20
Extreme 0.1972
6.50
5 years
0.20
Extreme 0.1972
17.00
10 years
0.20
Extreme 0.1972
1 512.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 01/15/01
Chief Tech/Sci/R&D Officer - 01/12/01
- -
Members of the board TitleAgeSince
Director/Board Member 60 01/06/01
Director/Board Member 77 11/20/11
Chairman 59 01/06/01
More insiders
Date Price Change Volume
18/24/18 0.2475 -3.70% 63 541
14/24/14 0.257 +6.64% 225,173
13/24/13 0.241 +0.21% 326,228
12/24/12 0.2405 -0.82% 162,213
11/24/11 0.2425 -6.01% 247,962

Delayed Quote Nyse, June 18, 2024 at 01:30 am IST

More quotes
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. SYN-004 (ribaxamase) is designed to degrade certain commonly used intravenous beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage. SYN-020 is a recombinant oral formulation of the enzyme intestinal alkaline phosphatase produced under current good manufacturing practice conditions and intended to treat both local GI and systemic diseases. Its research programs include VCN-11 Albumin Shield Technology and SYN-006, SYN-007, other oncolytic virus.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.257 USD
Average target price
2 USD
Spread / Average Target
+678.21%
Consensus